ABSTRACT Thyroid nodules are a very common finding and have a malignancy rate of 7%-15%. Some malignant nodules have an indolent behavior and may not affect mortality if left untreated. Active surveillance (AS) is a strategy to prevent overtreatment in patients with papillary thyroid microcarcinomas (PTMCs). This review was conducted to evaluate the status of AS for low-risk PTMC in Latin America, including cultural and logistical challenges, disease progression data, and financial viability. We searched PubMed (MEDLINE), SciELO, LILACS, and Web of Science for articles published after 2014 and enrolling adult Latin American patients. Articles cited in the selected studies were also retrieved. We analyzed the AS protocols, technical or logistical challenges, patient adherence, reasons for AS interruption, surgical conversion rates, duration of AS, and disease progression during AS in our region. Three articles were included in the analysis, all of which considered AS a viable option and reported tumor progression and outcomes similar to those reported in other countries. Neck ultrasound and serum levels of thyroglobulin, thyroid-stimulating hormone (TSH), thyroxine (T4), and antithyroglobulin antibodies were included in the follow-up. No cases of new distant metastases were reported, and the outcomes were favorable when surgery was required. Anxiety was the main reason for AS interruption. We conclude that AS can be an acceptable approach and is safe and effective in Latin America, although more prospective studies are needed to consolidate this strategy in our region. Adequate infrastructure, follow-up, and patient education, as well as multidisciplinary healthcare teams trained in conducting AS must be ensured for successful results. 7%15%. 715 7% 15%. 7 15 7%-15% untreated (AS PTMCs. PTMCs . (PTMCs) lowrisk low risk America challenges data viability MEDLINE, MEDLINE , (MEDLINE) SciELO LILACS 201 retrieved protocols adherence interruption rates region analysis countries thyroglobulin thyroidstimulating stimulating TSH, TSH (TSH) T4, T4 T (T4) followup. followup follow up. up follow-up required infrastructure followup, up, education results 7%15% 71 15% 1 7%-15 (PTMCs (MEDLINE 20 (TSH (T4 7%15 7%-1 2 (T 7%1 7%-